Program 01 Breast Cancer

乳腺癌项目 项目摘要/摘要 乳腺癌计划的使命是通过以下途径降低乳腺癌的发病率和死亡率 创新的基础研究和转化性研究以及开展有影响力的临床试验。该计划的成员 通力合作，在乳腺癌的整个过程中增进知识：从预防、筛查、 以及早期诊断对治疗和生存的影响。目标是提高治愈率和降低发病率。 在那些最终死于这种疾病的人和那些生活在治疗后期效果中的人中。 该方案有117名成员(73名初级成员和44名次要成员)，代表所有七个DF/HCC机构 和16个学术部门。2019年，用于该方案的同行审查赠款资金为810万美元 NCI的直接费用和其他赞助商的240万美元。在本供资期间，初级 项目成员发表了936篇与癌症相关的论文。其中，28%是跨机构的，22%是 方案内，42%是两个或更多DF/CC成员之间的方案间协作。 为了实现该计划的使命，我们的具体目标是：1)定义和解决 三阴性乳腺癌；2)改善乳腺癌预后的生物学特征 脑转移；3)提高乳腺癌免疫治疗的疗效；4)改善 个性化的本地-区域治疗；以及5)确保计划的进步服务于马萨诸塞州和 通过解决种族差距和获得癌症治疗的机会，在全国范围内实现这一目标。 这些目标与DF/CC战略计划密切一致，并将通过既定的和 用于协作跨学科研究、共享资源和统一的CCSG基础设施 加速将该计划的实验室发现转化为临床的临床试验设备。

Breast Cancer Program Project Summary / Abstract The mission of the Breast Cancer Program is to reduce morbidity and mortality from breast cancer through innovative basic and translational research and the conduct of impactful clinical trials. The Program’s members work collaboratively to advance knowledge across the continuum of breast cancer: from prevention, screening, and early diagnosis to treatment and survivorship. The goals are to increase cure rates and reduce morbidity among those who ultimately succumb to the disease and those who live with the late effects of therapy. The program has 117 members (73 primary and 44 secondary), representing all seven DF/HCC institutions and 16 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $8.1 million in direct costs from the NCI and $2.4 million from other sponsors. During the current funding period, primary Program members published 936 cancer-relevant papers. Of these, 28% were inter-institutional, 22% were intra-programmatic, and 42% were inter-programmatic collaborations between two or more DF/HCC members. To achieve the Program’s mission, our Specific Aims are to 1) Define and address the heterogeneity in triple-negative breast cancer; 2) Characterize the biology to improve outcomes from breast cancer metastases to the brain; 3) Improve the efficacy of immunotherapy for breast cancer; 4) Improve personalized local-regional therapy; and 5) Ensure that Program advances serve Massachusetts and the nation by addressing racial disparities and access to cancer care. These Aims align closely with the DF/HCC Strategic Plan and will be achieved through the established and invaluable CCSG infrastructure for collaborative transdisciplinary research, Shared Resources, and a unified clinical trials apparatus that accelerates translation of the Program’s laboratory discoveries to the clinic.